Germany’s CureVac NV started a mid-stage study testing the company’s experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter of 2020.
Novartis’ bid to expand the company’s $2.1 million-per-patient gene therapy Zolgensma to more spinal muscular atrophy patients faces a possible delay after U.S. regulators requested another study in older children getting the drug via a spinal infusion.
Fujifilm Holdings Corp. said a late-stage study of Avigan showed the antiviral drug reduced recovery times for Covid-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.
Gilead Sciences Inc. and Immunomedics announced that the companies entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.
Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
AstraZeneca should still know by year-end whether the company’s experimental vaccine protects people against coronavirus, as long as AZD1222 is cleared to resume trials soon, the drugmaker’s chief executive said amid doubts over the potential vaccine’s rollout.
AstraZeneca Plc paused global trials, including large late-stage studies, of the company’s experimental coronavirus vaccine because of an unexplained illness in a study participant.
Norwood, Massachusetts-based Corbus Pharmaceuticals’ shares plunged 77% at news the company’s lenabasum failed to hit the primary endpoint in the Phase III RESOLVE-1 trial of diffuse cutaneous systemic sclerosis (SSc).
Shares of Intercept Pharmaceuticals fell more than 10 percent following a decision by the company’s board of directors to cut 25 percent of headcount.
The U.S. House Oversight Committee decided to subpoena AbbVie Inc. to seek documents on the drugmaker’s blockbuster treatments, Humira and Imbruvica, as part of an investigation into drug pricing practices.
